In this webinar, the speakers will focus on how a comprehensive development plan (CDP) can increase efficiency and success rates in early drug development. They will also explain how Phase I Healthy Volunteer and Patient Hybrid Trials provide signals of potential efficacy and how CDPs are prepared.
TORONTO (PRWEB) MARCH 13, 2020
Join Paul Rothenberg, MD, PhD, Executive Director, Product Development Strategy, Covance Inc. and Amitava Ganguli, BSc (Hons/Pharm), MBChB, MRCP (Edin), Senior Medical Director, Medical & Scientific Affairs, Clinical Pharmacology Services, Covance Inc. in a live webinar on Thursday, March 19, 2020 at 1pm EST.
For novel drugs, demonstrating clinical “proof-of-concept” (POC) is a critical milestone on the road to success. Preparing a comprehensive development plan (CDP) – one that integrates early clinical trial designs and program strategy with other key disciplines (e.g., pre-clinical, regulatory, CMC, commercial) – can shorten overall timelines, reduce costs and increase success rates. Creating a thoughtful CDP that includes Phase I hybrid trials (with enrolment of healthy subjects and patients with the target disease) can help attain the earliest possible clinical POC. Planning a successful Phase I hybrid trial requires aligning the right therapeutic area, the right molecule, the right study design and endpoints, as well as considering regulatory requirements.
This free webinar explains what a CDP is and how pharmaceutical companies create and use CDPs, focusing on the central role of clinical pharmacologists in devising efficient drug development programs. We will explain what Phase I hybrid trials look like and how they provide an important advantage in early drug development.
For more information or to register for this event, visit Optimizing the Success of Phase I Hybrid Trials: The Role of a Comprehensive Early Development Plan.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Planning a successful Phase I hybrid trial requires aligning the right therapeutic area, the right molecule, the right study design and endpoints, as well as considering regulatory requirements.